Laboratory monitoring

实验室监测
  • 文章类型: Journal Article
    背景:在门诊诊所环境中,口服化疗(OC)实验室监测和随访存在许多低效率。当肿瘤学提供者的实验室测试结果报告和随访不一致时,开OC的癌症患者发生不良事件的风险较高。
    目的:本文的目的是通过确定门诊临床环境中患者与提供者之间可靠沟通的潜在障碍和机会来改善OC实验室监测。
    方法:文献综述发现76篇文章,其中15人被选中进行审查。对六个主题进行了综合和讨论。
    结果:医疗保健系统使用技术,标准途径,以及实验室测试后明确的患者-提供者沟通,以确保患者安全。实施和测试基于证据的解决方案和结构化框架,以识别门诊实验室监测和随访中的差距,可以提高OC治疗期间的患者满意度和安全性。
    BACKGROUND: There are many inefficiencies related to oral chemotherapy (OC) laboratory monitoring and follow-up in the ambulatory clinic setting. Patients with cancer prescribed OC have a higher risk of adverse events when there is inconsistent laboratory test result reporting and follow-up from their oncology provider.
    OBJECTIVE: The aim of this article is to improve OC laboratory monitoring by identifying potential barriers and opportunities for reliable communication between patients and providers in the outpatient clinical setting.
    METHODS: A literature review found 76 articles, of which 15 were selected for review. Six themes were synthesized and discussed.
    RESULTS: Healthcare systems use technology, standard pathways, and clear patient-provider communication following laboratory testing to ensure patient safety. Implementing and testing evidence-based solutions and structured frameworks to identify gaps in outpatient laboratory monitoring and follow-up can improve patient satisfaction and safety during OC treatment.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    Chronic hepatitis C virus infection is well-recognized as a common blood-borne infection with global public health impact affecting 3 to 5 million persons in the United States and more than 170 million persons worldwide. Chronic hepatitis C virus infection is associated with significant morbidity and mortality due to complications of liver cirrhosis and hepatocellular carcinoma. Current therapies with all-oral direct-acting antiviral agents are associated with high rates of sustained virologic response (SVR), generally exceeding 90%. SVR is associated with a reduced risk of liver cirrhosis, hepatic decompensation, need for liver transplantation, and both liver-related and all-cause mortality. However, a subset of patients who achieve SVR will remain at long-term risk for progression to cirrhosis, liver failure, hepatocellular carcinoma, and liver-related mortality. Limited evidence is available to guide clinicians on which post-SVR patients should be monitored vs discharged, how to monitor and with which tests, how frequently should monitoring occur, and for how long. In this clinical practice update, available evidence and expert opinion are used to generate best practice recommendations on the care of patients with chronic hepatitis C virus who have achieved SVR.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

公众号